Portal de Periódicos da CAPES

Worsening heart failure in Colombia: Analysis from RECOLFACA registry

2022; Elsevier BV; Volume: 47; Issue: 10 Linguagem: Inglês

10.1016/j.cpcardiol.2022.101301

1535-6280

Clara Saldarriaga, Juan Esteban Gómez‐Mesa, Alex A. Rivera Toquica, Patricia Rodríguez Gómez, Fernando Rivera Toquica, Guillermo Trout Guardiola, Marco Antonio De León Espitia, Edgar Eduardo Castro Osorio, Carlos Alberto Rentería Asprilla, Nelson Adolfo López Garzón, Armando Alcalá Hernández, J.L. Mendoza, Gary Andrés Baquero Lozano, Argemiro Ramón Martínez Carvajal, Luis Eduardo Echeverría,

Diabetes Treatment and Management

We aimed to describe and compare characteristics and outcomes of patients with a worsening heart failure episode included in the RECOLFACA registry during 2017-2019 vs population from VICTORIA trial. 2528 patients were included, 1890 (74.8%) had an ejection fraction <45% and a worsening episode. VICTORIA population was similar to RECOLFACA patients in mean age (67.3 vs 66.9 years), ejection fraction (28.9% vs 28.4%), the prevalence of COPD (17.1% vs 15.7%), and the median eGFR (61.5 vs 61.4 mL/min/1.73m2). RECOLFACA patients were mostly women, with a lower prevalence of atrial fibrillation, diabetes mellitus, and coronary artery disease. The 1-year heart failure hospitalization rate was 29.6% in the placebo group of VICTORIA, compared to 26.9% in RECOLFACA. Patients enrolled in the RECOLFACA that met the VICTORIA definition had more similar characteristics and outcomes compared to the VICTORIA population. There is an opportunity to improve this unmet need with the use of vericiguat.